- Tonix Pharmaceuticals (NASDAQ:TNXP) rises 5% in premarket after announcing preliminary results from animal studies of COVID-19 vaccine candidate, TNX-1800. The research is part of an ongoing collaboration between Southern Research Institute, the University of Alberta and Tonix.
- At day 14 after a single vaccination, all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies as compared to none in TNX-801 vaccinated control animals, or placebo group. The level of neutralizing anti-CoV-2 antibody production was similar between the low and high dose TNX-1800 groups.
- The company plans to initiate human clinical trials with the vaccine candidate in 2021.
- TNX-1800 is a live modified horsepox virus vaccine that is designed to express the Spike protein of the SARS-CoV-2 virus and to elicit a predominant T cell response.
- https://seekingalpha.com/news/3636465-tonix-pharmas-covidminus-19-vaccine-candidate-shows-encouraging-preclinical-action
Monday, November 16, 2020
Tonix COVID-19 vaccine candidate shows encouraging preclinical action
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.